Importantly, LZQ‐02‐023‐01 did not cause substantial weight loss (Figure S6a–c, Supporting Information) or discernible toxic effects on other organs (Figure S6d–i, Supporting Information), except that a reduction in spleen weight was observed in these two types of GC mice (Figure S6f,h, Supporting Information), indicating a lower cancer burden.[31, 32] Therefore, LZQ‐02‐023‐01 is a potent METTL10 inhibitor capable of mitigating GC progression. Here, EEF1AKMT2 is linked to gastric cancer.